Claims for Patent: 9,284,307
✉ Email this page to a colleague
Summary for Patent: 9,284,307
Title: | Macrocyclic serine protease inhibitors |
Abstract: | Provided herein are macrocyclic serine protease inhibitor compounds, for example, of Formula Ia or Ib, pharmaceutical compositions comprising the compounds, and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host in need thereof. ##STR00001## |
Inventor(s): | Parsy; Christophe Claude (Jacou, FR), Alexandre; Francois-Rene (Montpellier, FR), Leroy; Frederic (Montarnaud, FR), Convard; Thierry (Sathonay-Camp, FR), Surleraux; Dominique (Wauthier-Braine, BE) |
Assignee: | Idenix Pharmaceuticals LLC (Cambridge, MA) |
Application Number: | 12/850,534 |
Patent Claims: | 1. A compound of Formula Ia or Ib: ##STR00174## or a single enantiomer, a racemic mixture, a mixture of diastereomers, or an isotopic variant thereof; or a pharmaceutically
acceptable salt thereof; wherein: R.sup.5 is --NHS(O).sub.2R.sup.8; wherein R.sup.8 is 1-methylcyclopropyl or 1-ethynylcyclopropyl; L is --O-- or --OC(O)NH--; R.sup.6 is methoxy-fluoro-(isopropylthiazolyl)quinolinyl,
methoxy-chloro-(isopropyl-thiazolyl)quinolinyl, methoxy-bromo-(isopropylthiazolyl)quinolinyl, methoxy-methyl-(isopropylthiazolyl)quinolinyl, dimethoxy-(isopropylthiazolyl)quinolinyl, difluoromethyl-chloro-(isopropylthiazolyl)quinolinyl,
difluoromethyl-methyl-(isopropylthiazolyl)quinolinyl, trifluoromethyl-methyl-(isopropyl-thiazolyl)quinolinyl, methanesulfonamido-chloro-(isopropylthiazolyl)quinolinyl, methane-sulfonamido-methyl-(isopropylthiazolyl)quinolinyl,
methoxy-fluoro-(trifluoromethylthiazolyl)-quinolinyl, methoxy-chloro-(trifluoro-methylthiazolyl)quinolinyl, methoxy-bromo-(trifluoromethylthiazolyl)quinolinyl, methoxy-methyl-(trifluoromethylthiazolyl)quinolinyl,
dimethoxy-(trifluoromethylthiazolyl)quinolinyl, methanesulfonamido-methyl-(trifluoromethylthiazolyl)quinolinyl, methoxy-chloro-(ethenyl-thiazolyl)quinolinyl, methoxy-chloro-(ethynylthiazolyl)quinolinyl, methoxy-methyl-(ethynyl-thiazolyl)quinolinyl,
methoxy-chloro-(cyanothiazolyl)quinolinyl, methoxy-chloro-(methyl-thiazolyl)quinolinyl, methoxy-chloro-(cyclopropylthiazolyl)quinolinyl, methoxy-chloro-(cyclobutylthiazolyl)quinolinyl, chloro-methoxy-(isopropyl-1H-pyrazolyl)quinolinyl,
methyl-methoxy-(isopropyl-1H-pyrazolyl)quinolinyl, chloro-methoxy-(trifluoromethyl-1H-pyrazolyl)-quinolinyl, methyl-methoxy-(trifluoromethyl-1H-pyrazolyl)quinolinyl, methoxy-fluoro-(isopropylisoxazolyl)quinolinyl,
methoxy-chloro-(isopropyl-isoxazolyl)quinolinyl, methoxy-bromo-(isopropylisoxazolyl)quinolinyl, methoxy-methyl-(isopropylisoxazolyl)quinolinyl, dimethoxy-(isopropylisoxazolyl)quinolinyl; and Q.sup.1 is --N(R.sup.17)--; wherein R.sup.17 is independently
hydrogen, C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.3-7 cycloalkyl, C.sub.6-14 aryl, C.sub.7-15 aralkyl, heteroaryl, or heterocyclyl; Q.sup.2 has the structure of: ##STR00175## wherein: Y is a bond, --O--, --S--, --S(O)--,
--S(O).sub.2--, or --N(R.sup.Y)--, wherein R.sup.Y is hydrogen, C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.3-7 cycloalkyl, C.sub.6-14 aryl, C.sub.7-15 aralkyl, --C(O)R.sup.Ya, --C(O)OR.sup.Ya, --C(O)NR.sup.YbR.sup.Yc,
--S(O).sub.2NR.sup.YbR.sup.Yc, or --S(O).sub.2R.sup.Ya; where each R.sup.Ya, R.sup.Yb, and R.sup.Yc is independently hydrogen, C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.3-7 cycloalkyl, C.sub.6-14 aryl, C.sub.7-15 aralkyl, heteroaryl,
or heterocyclyl; q is an integer of 0, 1, 2, 3, or 4; r is an integer of 0, 1, 2, 3, or 4; and m is an integer of 0 or 1; and n is an integer of 1 or 2; with the proviso that the sum of m and n is 2.
2. The compound of claim 1, wherein R.sup.17 is hydrogen or methyl. 3. The compound of claim 1, wherein R.sup.6 is 7-methoxy-8-fluoro-2-(4-isopropylthiazol-2-yl)quinolin-4-yl, 7-methoxy-8-chloro-2-(4-isopropylthiazol-2-yl)quinolin-4-yl, 7-methoxy-8-bromo-2-(4-isopropylthiazol-2-yl)quinolin-4-yl, 7-methoxy-8-methyl-2-(4-isopropylthiazol-2-yl)quinolin-4-yl, 5,7-dimethoxy-2-(4-isopropylthiazol-2-yl)quinolin-4-yl, 6-chloro-7-methoxy-2-(4-isopropyl-thiazol-2-yl)quinolin-4-yl, 6-methoxy-7-chloro-2-(4-isopropylthiazol-2-yl)quinolin-4-yl, 6-methoxy-8-methyl-2-(4-isopropylthiazol-2-yl)quinolin-4-yl, 6-methoxy-8-chloro-2-(4-isopropylthiazol-2-yl)quinolin-4-yl, 7-difluoromethyl-8-methyl-2-(4-isopropylthiazol-2-yl)quinolin-4-yl, 7-difluoromethyl-8-chloro-2-(4-isopropylthiazol-2-yl)quinolin-4-yl, 6-trifluoromethyl-8-methyl-2-(4-isopropylthiazol-2-yl)quinolin-4-yl, 7-trifluoromethyl-8-methyl-2-(4-isopropylthiazol-2-yl)quinolin-4-yl, 7-trifluoromethyl-8-chloro-2-(4-isopropyl-thiazol-2-yl)quinolin-4-yl, 7-methanesulfonamido-8-methyl-2-(4-isopropylthiazol-2-yl)-quinolin-4-yl, 7-methanesulfonamido-8-chloro-2-(4-isopropylthiazol-2-yl)quinolin-4-yl, 6-methyl-8-difluoromethyl-2-(4-isopropylthiazol-2-yl)quinolin-4-yl, 7-methoxy-8-fluoro-2-(4-trifluoromethylthiazol-2-yl)quinolin-4-yl, 7-methoxy-8-chloro-2-(4-trifluoromethylthiazol-2-yl)quinolin-4-yl, 7-methoxy-8-bromo-2-(4-trifluoromethyl-thiazol-2-yl)quinolin-4-yl, 7-methoxy-8-methyl-2-(4-trifluoromethylthiazol-2-yl)quinolin-4-yl, 5,7-dimethoxy-2-(4-trifluoromethylthiazol-2-yl)quinolin-4-yl, 6-methoxy-7-chloro-2-(4-trifluoromethylthiazol-2-yl)quinolin-4-yl, 6-methoxy-8-methyl-2-(4-trifluoromethylthiazol-2-yl)quinolin-4-yl, 7-methanesulfonamido-8-methyl-2-(4-trifluoromethylthiazol-2-yl)quinolin-4- -yl, 7-methoxy-8-chloro-2-(4-ethenylthiazol-2-yl)quinolin-4-yl, 7-methoxy-8-chloro-2-(4-ethynylthiazol-2-yl)quinolin-4-yl, 7-methoxy-8-methyl-2-(4-ethynylthiazol-2-yl)quinolin-4-yl, 7-methoxy-8-chloro-2-(4-cyanothiazol-2-yl)quinolin-4-yl, 7-methoxy-8-chloro-2-(4-methylthiazol-2-yl)quinolin-4-yl, 7-methoxy-8-chloro-2-(4-cyclopropylthiazol-2-yl)quinolin-4-yl, 7-methoxy-8-chloro-2-(4-cyclobutylthiazol-2-yl)quinolin-4-yl, 7-methoxy-8-fluoro-2-(2-isopropylthiazol-4-yl)quinolin-4-yl, 7-methoxy-8-chloro-2-(2-isopropylthiazol-4-yl)quinolin-4-yl, 7-methoxy-8-bromo-2-(2-isopropylthiazol-4-yl)quinolin-4-yl, 7-methoxy-8-methyl-2-(2-isopropylthiazol-4-yl)quinolin-4-yl, 5,7-dimethoxy-2-(2-isopropylthiazol-4-yl)quinolin-4-yl, 6-methoxy-7-chloro-2-(2-isopropylthiazol-4-yl)quinolin-4-yl, 6-methoxy-8-methyl-2-(2-isopropylthiazol-4-yl)quinolin-4-yl, 7-methoxy-8-chloro-2-(2-trifluoromethylthiazol-4-yl)quinolin-4-yl, 7-methoxy-8-methyl-2-(2-trifluoromethylthiazol-4-yl)quinolin-4-yl, 8-chloro-7-methoxy-2-(3-isopropyl-1H-pyrazol-1-yl)quinolin-4-yl, 8-methyl-7-methoxy-2-(3-isopropyl-1H-pyrazol-1-yl)-quinolin-4-yl, 8-chloro-7-methoxy-2-(3-trifluoromethyl-1H-pyrazol-1-yl)quinolin-4-yl, 8-methyl-7-methoxy-2-(3-trifluoromethyl-1H-pyrazol-1-yl)quinolin-4-yl, 7-methoxy-8-fluoro-2-(5-isopropylisoxazol-3-yl)-quinolin-4-yl, 7-methoxy-8-chloro-2-(5-isopropylisoxazol-3-yl)quinolin-4-yl, 7-methoxy-8-bromo-2-(5-isopropylisoxazol-3-yl)quinolin-4-yl, 7-methoxy-8-methyl-2-(5-isopropyl-isoxazol-3-yl)quinolin-4-yl, 5,7-dimethoxy-2-(5-isopropylisoxazol-3-yl)quinolin-4-yl, 6-methoxy-7-chloro-2-(5-isopropylisoxazol-3-yl)quinolin-4-yl, or 6-methoxy-8-methyl-2-(5-isopropylisoxazol-3-yl)quinolin-4-yl. 4. The compound of claim 1, wherein m is 0. 5. The compound of claim 1, wherein m is 1. 6. The compound of claim 1, wherein n is 1. 7. The compound of claim 1, wherein n is 2. 8. The compound of claim 1, wherein R.sup.8 is 1-methylcyclopropyl. 9. The compound of claim 1, wherein the compound is: ##STR00176## or a single enantiomer, a racemic mixture, a mixture of diastereomers, or an isotopic variant thereof or a pharmaceutically acceptable salt thereof. 10. A pharmaceutical composition comprising the compound of claim 1, and one or more pharmaceutically acceptable carriers. 11. The pharmaceutical composition of claim 10, further comprising a second antiviral agent. 12. The pharmaceutical composition of claim 11, wherein the second antiviral agent is selected from an interferon, ribavirin, an interleukin, an NS3 protease inhibitor, a cysteine protease inhibitor, a phenathrenequinone, a thiazolidine, a benzanilide, a helicase inhibitor, a polymerase inhibitor, a nucleotide analogue, a liotoxin, acerulenin, an antisense phosphorothioate oligodeoxynucleotide, an inhibitor of IRES-dependent translation, or a ribozyme. 13. The pharmaceutical composition of claim 11, wherein the second antiviral agent is an interferon. 14. The pharmaceutical composition of claim 13, wherein the interferon is selected from pegylated interferon alpha 2a, interferon alfahcon-1, natural interferon, albuferon, interferon beta-1a, omega interferon, interferon alpha, interferon gamma, interferon tau, interferon delta, or interferon gamma-1b. 15. The pharmaceutical composition of claim 10, wherein the composition is formulated for single dose administration. 16. The pharmaceutical composition of claim 10, wherein the composition is formulated as oral, parenteral, or intravenous dosage form. 17. The pharmaceutical composition of claim 16, wherein the oral dosage form is a tablet or capsule. 18. The pharmaceutical composition of claim 10, wherein the compound is administered in a dose of about 0.5 milligram to about 1,000 milligram daily. |
Details for Patent 9,284,307
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Biogen Inc. | AVONEX | interferon beta-1a | For Injection | 103628 | 05/17/1996 | ⤷ Try a Trial | 2029-08-05 |
Biogen Inc. | AVONEX | interferon beta-1a | Injection | 103628 | 05/28/2003 | ⤷ Try a Trial | 2029-08-05 |
Biogen Inc. | AVONEX | interferon beta-1a | Injection | 103628 | 02/27/2012 | ⤷ Try a Trial | 2029-08-05 |
Emd Serono, Inc. | REBIF | interferon beta-1a | Injection | 103780 | 03/07/2002 | ⤷ Try a Trial | 2029-08-05 |
Emd Serono, Inc. | REBIF | interferon beta-1a | Injection | 103780 | 12/17/2004 | ⤷ Try a Trial | 2029-08-05 |
Emd Serono, Inc. | REBIF | interferon beta-1a | Injection | 103780 | 12/21/2012 | ⤷ Try a Trial | 2029-08-05 |
Horizon Therapeutics Ireland Dac | ACTIMMUNE | interferon gamma-1b | Injection | 103836 | 02/25/1999 | ⤷ Try a Trial | 2029-08-05 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.